BRIEF-EU regulator recommends condition approval of Shire's chronic hypoparathyroidism medicine
February 24, 2017 at 07:22 AM EST
* Recommends conditional marketing authorisation of Shire's orphan medicine Natpar for chronic hypoparathyroidism
